Omotola Olasupo and Colleagues Present Comparative Safety of Hemophilia Therapies in Canada
RPTH Journal shared on LinkedIn:
”Comparative safety of hemophilia therapies in Canada
Real-world comparative safety data for hemophilia therapies remain limited.
This study leverages national registry data to better understand adverse drug reactions across commonly used treatments using Canadian registry data over 5 years
- Allergic reactions were the most frequently reported adverse drug reactions
- A higher number of reported events was observed with emicizumab, although novelty bias cannot be excluded
- No inhibitor development was reported with emicizumab or bypassing agents
These findings provide important real-world insights into the relative safety of therapies used in hemophilia A and B, while highlighting the need for continued pharmacovigilance as treatment landscapes evolve.”
Read the full article here.
Article: Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study
Authors: Omotola Olasupo, Emma Iserman, Arun Keepanasseril, Quazi Ibrahim, Zainab Salim Ali Al-Housni, Federico Germini, Jean-Eric Tarride, Lawrence Mbuagbaw, Shannon Jackson, Ingrid Blydt-Hansen, Michelle Bech, Celina Woo, Mark Belletrutti, Alfonso Iorio, Davide Matino: the Association of Hemophilia Clinic Directors of Canada (AHCDC)
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event
-
Sep 25, 2026, 05:47Omid Seidizadeh: Evolutionary Constraint and Population Variation Across Coagulation Genes
-
Sep 25, 2026, 05:40Gerald Bertrand: Presenting UMi-NGS Non-Invasive Foetal HPA Genotyping at DGTI 2026
-
Sep 25, 2026, 05:33Urge Congress to support the Sickle Cell Disease Comprehensive Care Act – ASH
-
Sep 25, 2026, 05:24Isabelle Mahé: Reduced-Dose Apixaban in Extended CAT Treatment
-
Sep 25, 2026, 05:15Maria Cherska: High Cholesterol Isn’t Always Diet or Lifestyle – Sometimes It’s Genetic